STRS Ohio’s Lineage Cell Therapeutics LCTX Stock Holding History

STRS Ohio’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-282,700	Closed	-$435K	–	2173
2022 Q1	$435K	Hold	282,700	–	–	﹤0.01%	1498
2021 Q4	$692K	Hold	282,700	–	–	﹤0.01%	1357
2021 Q3	$712K	Hold	282,700	–	–	﹤0.01%	1340
2021 Q2	$805K	Buy	+282,700	New	+$731K	﹤0.01%	1329

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

STRS Ohio's LCTX Position: Q2 2022 in Review

STRS Ohio sold out of Lineage Cell Therapeutics (LCTX) in Q2 2022, closing a stake of 282,700 shares — an estimated $435K sold.

STRS Ohio first reported a position in LCTX in Q2 2021 and held it in 4 quarters. The position peaked at $805K in Q2 2021. 101 funds tracked by Wall St. Rank hold LCTX as of Q2 2022.

STRS Ohio reported no remaining Lineage Cell Therapeutics position as of Q2 2022 after selling out during the quarter.
STRS Ohio sold 282,700 Lineage Cell Therapeutics shares in Q2 2022, an estimated $435K.
STRS Ohio first reported a position in Lineage Cell Therapeutics in Q2 2021 and held it in 4 quarters.
STRS Ohio's Lineage Cell Therapeutics position peaked at $805K in Q2 2021.
101 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.